Company: SUPN
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0001104659-25-042531
Chunk: 10

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 10
---
15 members. At our Annual Meeting, two directors are to be elected. The Board of Directors recommends that stockholders elect Carrolee Barlow, M.D., Ph.D and Jack A. Khattar to hold office until the 2028 Annual Meeting of Stockholders or until their respective successors have been elected and qualified. This slate of directors, recommended and approved by the Board of Directors, was determined following an assessment by the Board of Directors of the skill set and experience of such persons. Each of the nominees named below was re-elected as a director at the Annual Meeting of Stockholders held on June 17, 2022. The persons designated as proxies in the accompanying proxy card intend to vote “FOR” each such nominee, unless a contrary instruction is indicated on the proxy card. If for any reason the nominee should become unavailable for election, the persons designated as proxies in the proxy card may vote the proxy for the election of another person nominated as a substitute by the Board of Directors, if any person is so nominated. We have no reason to believe that the nominees will be unable or unwilling to serve if elected, and the nominees have expressed their intention to serve the entire term for which election is sought. The proxies cannot be voted for a greater number of persons than the number of nominees named, which is two nominees. The following table sets forth below the name, age, service dates and respective position with the Company of each member of our Board of Directors:

| Name                                         | ​ | ​ | Age |   |    |   | ​ | ​ | Director Since |   |      |   | ​ | ​ | Position                                                   | ​ |
| Class I Directors (Term maturing in 2025)    | ​ | ​ | ​   | ​ |  ​ | ​ | ​ | ​ | ​              | ​ |    ​ | ​ | ​ | ​ | ​                                                          | ​ |
| Carrolee Barlow, M.D., Ph.D.(1)(4)           | ​ | ​ | ​   | ​ | 61 | ​ | ​ | ​ | ​              | ​ | 2018 | ​ | ​ | ​ | Director                                                   | ​ |
| Jack A. Khattar                              | ​ | ​ | ​   | ​ | 63 | ​ | ​ | ​ | ​              | ​ | 2005 | ​ | ​ | ​ | President, Chief Executive Officer and Secretary, Director | ​ |
| Class II Directors (Term maturing in 2026):  |